BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 30816444)

  • 1. MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation.
    Lee J; An S; Jung JH; Kim K; Kim JY; An IS; Bae S
    Int J Oncol; 2019 May; 54(5):1833-1842. PubMed ID: 30816444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial E3 Ubiquitin Protein Ligase 1 Mediates Cigarette Smoke-Induced Endothelial Cell Death and Dysfunction.
    Kim SY; Kim HJ; Park MK; Huh JW; Park HY; Ha SY; Shin JH; Lee YS
    Am J Respir Cell Mol Biol; 2016 Feb; 54(2):284-96. PubMed ID: 26203915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer.
    Kim SY; Kim HJ; Kang SU; Kim YE; Park JK; Shin YS; Kim YS; Lee K; Kim CH
    Oncotarget; 2015 Oct; 6(32):33382-96. PubMed ID: 26450902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
    Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
    BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
    Li C; Liu VW; Chan DW; Yao KM; Ngan HY
    Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosstalk between HSPA5 arginylation and sequential ubiquitination leads to AKT degradation through autophagy flux.
    Kim HJ; Kim SY; Kim DH; Park JS; Jeong SH; Choi YW; Kim CH
    Autophagy; 2021 Apr; 17(4):961-979. PubMed ID: 32164484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondrial E3 ubiquitin ligase 1 promotes autophagy flux to suppress the development of clear cell renal cell carcinomas.
    Yuan Y; Li X; Xu Y; Zhao H; Su Z; Lai D; Yang W; Chen S; He Y; Li X; Liu L; Xu G
    Cancer Sci; 2019 Nov; 110(11):3533-3542. PubMed ID: 31489722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer.
    Kim SY; Kim HJ; Kim HJ; Kim DH; Han JH; Byeon HK; Lee K; Kim CH
    Autophagy; 2018; 14(3):385-403. PubMed ID: 29260979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phenomenon of acquired resistance to metformin in breast cancer cells: The interaction of growth pathways and estrogen receptor signaling.
    Scherbakov AM; Sorokin DV; Tatarskiy VV; Prokhorov NS; Semina SE; Berstein LM; Krasil'nikov MA
    IUBMB Life; 2016 Apr; 68(4):281-92. PubMed ID: 26892736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells
    Tang JC; An R; Jiang YQ; Yang J
    Cancer Res Treat; 2017 Jul; 49(3):778-789. PubMed ID: 27857021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer.
    Wen KC; Sung PL; Wu ATH; Chou PC; Lin JH; Huang CF; Yeung SJ; Lee MH
    J Ovarian Res; 2020 Aug; 13(1):95. PubMed ID: 32825834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
    Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
    Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway.
    Fu YL; Zhang QH; Wang XW; He H
    Eur Rev Med Pharmacol Sci; 2017 Mar; 21(5):1169-1175. PubMed ID: 28338172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
    Dalva-Aydemir S; Bajpai R; Martinez M; Adekola KU; Kandela I; Wei C; Singhal S; Koblinski JE; Raje NS; Rosen ST; Shanmugam M
    Clin Cancer Res; 2015 Mar; 21(5):1161-71. PubMed ID: 25542900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
    Gadducci A; Biglia N; Tana R; Cosio S; Gallo M
    Crit Rev Oncol Hematol; 2016 Sep; 105():73-83. PubMed ID: 27378194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
    Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
    Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
    Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.